Key result
Systemic delivery of human cardiac stem cell-derived exosomes improved heart function and decreased apoptosis and fibrosis in a mouse model of doxorubicin-induced dilated cardiomyopathy.
Why the study?
Does systemic delivery of human cardiac stem cell-derived exosomes improve heart function in a mouse model of doxorubicin-induced dilated cardiomyopathy?
Does systemic delivery of human cardiac stem cell-derived exosomes improve heart function in a mouse model of doxorubicin-induced dilated cardiomyopathy?
Intravenous delivery of human cardiac stem cell-derived exosomes improves heart function and reduces apoptosis and fibrosis in a mouse model of doxorubicin-induced dilated cardiomyopathy without causing adverse immune reactions.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for exosome therapy in chemotherapy cardiomyopathy; leaves open translation to human trials.
Vandergriff et al. (2015) studied doxorubicin induced dilated cardiomyopathy. human cardiac stem cell-derived exosomes (CSC-XOs) was evaluated on heart function, apoptosis, and fibrosis. Systemic delivery of human cardiac stem cell-derived exosomes improved heart function and decreased apoptosis and fibrosis in a mouse model of doxorubicin-induced dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: